Angiotech Biomaterials

Angiotech Biomaterials was a specialized division of Angiotech Pharmaceuticals focused on the research, development, and manufacture of advanced biomaterials and surgical sealants. The company's core expertise lay in collagen-based technologies and synthetic polymer chemistry, which were utilized to create medical device coatings and wound management products. One of its most significant contributions was the development of the paclitaxel-eluting coating for the Taxus coronary stent in partnership with Boston Scientific. In 2011, the entity was acquired by Royal DSM for $38.5 million and integrated into the DSM Biomedical business unit. The acquisition included the company's primary manufacturing and R&D facility located in Palo Alto, California.